info@biomedres.us   +1 (720) 414-3554   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Case ReportOpen Access

Irreversible Bone Marrow Failure after Cladribine Treatment in a Patient with Hairy Cell Leukemia

Volume 4 - Issue 3

Eugenio Galli*, Marianna Criscuolo, Luana Fianchi, Andrea P. Bacigalupo and Livio Pagano

  • Author Information Open or Close
    • Istituto di Ematologia, Polo di Onco-Ematologia, Fondazione Policlinico Agostino Gemelli Università Cattolica del Sacro Cuore

    *Corresponding author:Dott Eugenio Galli, Istituto di Ematologia, Polo Di Onco-EmatologiaFondazione Policlinico A Gemelli-Università Cattolica del Sacro Cuore, Largo F. Vito 1 I-0068 Roma Italia

Received: April 26, 2018;   Published: May 08,2018

DOI: 10.26717/BJSTR.2018.04.001046

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Here we describe a 67 year old female affected by hairy cell leukemia (HCL) treated with 2-CDA, who developed prolonged bone marrow failure. Severe and persistent pancytopenia led to lethal pulmonary aspergillosis on day +85 of treatment. We have then reviewed literature in order to better understand occurrence of neutropenia and infections in this kind of patients. The most prominent side effect of 2CDA has been reported to be myelosuppression, but only one irreversible failure has been described until now.imately dead from serious complications. The rare and special gastrointestinal lesions after acute diquat poisoning is worth for us to explore.

Keywords: Cladribine; Hairy cell Leukemia; Aspergillosis; Aplasia

Abstract| Introduction| Case Report| Discussion| References|